Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
Peptide combats cancer progression in animal model
An article published in Scientific Reports describes a study demonstrating the effectiveness of a peptide developed by Brazilian…
Proteomic study of 2,002 tumours identifies 11 pan-cancer molecular subtypes across 14 types of cancer
A new study that analyzed protein levels in 2,002 primary tumours from 14 tissue-based cancer…
Indigenous Australians at higher risk of HPV throat cancers
Researchers from the University of Adelaide have found that throat cancers caused by human papilloma…
ASTRO 2022: Three-week course of radiation safe and effective for patients with early-stage breast cancer
- Antibody-based therapy eliminates circulating tumour cells in mouse models of breast and pancreatic cancer
- Unveiling the true IMPACT of breast cancer trials research conducted by QUT’s Australian Centre for Philanthropy and Nonprofit Studies
- Mechanical properties show rigid breast tumours can contain soft cancer cells
COSA 2018: Cost of cancer treatment
Australia’s leading cancer charities have joined together to call for greater commitment and transparency from doctors and healthcare providers to…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.